摘要
目的评价唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效及不良反应。方法所有病例均为乳腺癌骨转移患者,其中唑来膦酸组29例,帕米膦酸二钠组25例。给药方法:唑来膦酸4mg+生理盐水50ml静脉滴注15min;帕米膦酸二钠60mg+生理盐水500ml静脉滴注4h;均每4周1次,共3次。记录治疗效果及不良反应。结果疼痛缓解情况:唑来膦酸组完全缓解(CR)15例(51.7%),部分缓解(PR)9例(31.0%),临床获益[CR+PR+轻度缓解(MR)]93.0%;帕米膦酸二钠组CR11例(44.0%),PR7例(28.0%),临床获益88.0%。主要不良反应为发热、感冒样症状、低钙血症。结论唑来膦酸与帕米膦酸二钠对乳腺癌转移性骨痛有较好的疗效;两药的治疗效果及不良反应相似,但唑来膦酸使用更为方便。
Objective To evaluate the short-term efficacy and side effects of Zometa （zoledronic acid） and Aredia （pamidronate） therapy for bone metastases from breast cancer . Methods A total of 54 breast cancer patients with bone metastases who were evaluable were enrolled and divided into the Zometa group （29 cases） and the Aredia group （25 cases）. In the Zometa group intravenous infusion of Zometa 4 mg in 50ml normal saline over 15 minutes was administered every 4 weeks for 12 weeks; in the Aredia group intravenous infusion of Aredia 60 mg in 500 ml normal saline over 4 hours was administered every 4 weeks for 12 weeks. The clinical efficacy and side effects were observed and recorded concun：ently. Results In the Zometa group 15 cases （51.7%） had complete response （CR） and 9 cases （31.0%） partial response （PR） for relief of bone pain, with the clinical benefit response （ CR ＋ PR ＋ MR） 93.0%. While in the Aredia group 11 cases （44.0%） had CR and 7 cases （28.0%） had PR, with the clinical benefit response 88.0%. Major side effects included febrilis, symptoms of catching cold and hypocalcemia. Conclusions Zometa and Aredia are both effective and generally well tolerated in treating bone metastasis from breast cancer. There is no difference in clinical efficacy and side effects between the two drugs, but Zometa is more convenient than Aredia in application.
出处
《中华乳腺病杂志（电子版）》
CAS
2008年第4期10-13,共4页
Chinese Journal of Breast Disease(Electronic Edition)
